BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 15114263)

  • 1. Serum cathepsin B activity during regression of Morris hepatoma 5123 D.
    Fedorowski A; Steciwko A; Rabczyński J
    Med Sci Monit; 2004 May; 10(5):BR144-50. PubMed ID: 15114263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum level of cathepsin B and its density in men with prostate cancer as novel markers of disease progression.
    Miyake H; Hara I; Eto H
    Anticancer Res; 2004; 24(4):2573-7. PubMed ID: 15330217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total and lipid-bound plasma sialic acid as diagnostic markers in colorectal cancer patients: correlation with cathepsin B expression in progression to Dukes stage.
    Sebzda T; Saleh Y; Gburek J; Warwas M; Andrzejak R; Siewinski M; Rudnicki J
    J Exp Ther Oncol; 2006; 5(3):223-9. PubMed ID: 16528972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Significance of cathepsin B and D in physiologic and pathologic processes].
    Olszewska D; Drewa T; Makarewicz R; Drewa J; Woźniak A; Maciak R
    Pol Merkur Lekarski; 2001 Jan; 10(55):65-70. PubMed ID: 11320558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Earthworm fibrinolytic enzyme: anti-tumor activity on human hepatoma cells in vitro and in vivo.
    Chen H; Takahashi S; Imamura M; Okutani E; Zhang ZG; Chayama K; Chen BA
    Chin Med J (Engl); 2007 May; 120(10):898-904. PubMed ID: 17543180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chiral cyclopalladated complexes derived from N,N-dimethyl-1-phenethylamine with bridging bis(diphenylphosphine)ferrocene ligand as inhibitors of the cathepsin B activity and as antitumoral agents.
    Bincoletto C; Tersariol IL; Oliveira CR; Dreher S; Fausto DM; Soufen MA; Nascimento FD; Caires AC
    Bioorg Med Chem; 2005 Apr; 13(8):3047-55. PubMed ID: 15781414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-frequency electromagnetic stimulation may lead to regression of Morris hepatoma in buffalo rats.
    Fedorowski A; Steciwko A; Rabczynski J
    J Altern Complement Med; 2004 Apr; 10(2):251-60. PubMed ID: 15165406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas.
    Gondi CS; Lakka SS; Yanamandra N; Olivero WC; Dinh DH; Gujrati M; Tung CH; Weissleder R; Rao JS
    Cancer Res; 2004 Jun; 64(12):4069-77. PubMed ID: 15205313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis.
    Lakka SS; Gondi CS; Yanamandra N; Olivero WC; Dinh DH; Gujrati M; Rao JS
    Oncogene; 2004 Jun; 23(27):4681-9. PubMed ID: 15122332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of Ukrain and cyclophosphamide administration on HA-1 murine hepatoma and LS lymphoma on aspartic proteinase cathepsin D.
    Djanayeva SJ; Korolenko TA; Svechnikova IG; Falameyeva OV; Korolenko E; Kaledin VI; Nowicky J
    Drugs Exp Clin Res; 2000; 26(5-6):293-9. PubMed ID: 11345041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Actin content and actin polymerization in hepatoma Morris 5123 tumor bearing rats after treatment with cysteine protease inhibitor and vitamin E.
    Sebzda T; Saleh Y; Malicka-Blaszkiewicz M; Nowak D; Siewinski M; Ziolkowski P; Kopec W
    J Exp Ther Oncol; 2005; 5(1):23-9. PubMed ID: 16416598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous expression of Cathepsins B and K in pulmonary adenocarcinomas and squamous cell carcinomas predicts poor recurrence-free and overall survival.
    Cordes C; Bartling B; Simm A; Afar D; Lautenschläger C; Hansen G; Silber RE; Burdach S; Hofmann HS
    Lung Cancer; 2009 Apr; 64(1):79-85. PubMed ID: 18760860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Construction of autocatalytic caspase-3 driven by amplified human telomerase reverse transcriptase promoter and its enhanced efficacy of inducing apoptosis in human ovarian carcinoma].
    Song Y; Shen K; He CX
    Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):617-22. PubMed ID: 17983518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer.
    Vasiljeva O; Papazoglou A; Krüger A; Brodoefel H; Korovin M; Deussing J; Augustin N; Nielsen BS; Almholt K; Bogyo M; Peters C; Reinheckel T
    Cancer Res; 2006 May; 66(10):5242-50. PubMed ID: 16707449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NTP toxicology and carcinogenesis studies of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (CAS No. 57465-28-8) in female Harlan Sprague-Dawley rats (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2006 Jan; (520):4-246. PubMed ID: 16628245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cathepsins B and D activity and activity ratios in normal ovaries, benign ovarian neoplasms, and epithelial ovarian cancer.
    Downs LS; Lima PH; Bliss RL; Blomquist CH
    J Soc Gynecol Investig; 2005 Oct; 12(7):539-44. PubMed ID: 16202931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipopolysaccharide accelerates caspase-independent but cathepsin B-dependent death of human lung epithelial cells.
    Tang PS; Tsang ME; Lodyga M; Bai XH; Miller A; Han B; Liu M
    J Cell Physiol; 2006 Nov; 209(2):457-67. PubMed ID: 16894574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.
    Tumminello FM; Flandina C; Crescimanno M; Leto G
    Biomed Pharmacother; 2008 Feb; 62(2):130-5. PubMed ID: 17728092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers.
    Herszényi L; István G; Cardin R; De Paoli M; Plebani M; Tulassay Z; Farinati F
    Eur J Cancer Prev; 2008 Oct; 17(5):438-45. PubMed ID: 18714186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
    Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
    Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.